Literature DB >> 7490315

Production and characterisation of an antimelanoma monoclonal antibody KBA.62 using a new melanoma cell line reactive on paraffin wax embedded sections.

E Cohen-Knafo1, T al Saati, J Aziza, E Ralfkiaer, J Selves, B Gorguet, G Delsol.   

Abstract

AIMS--To generate new monoclonal antibodies directed against melanoma associated antigens using a new melanoma cell line, KAL. METHODS--The melanoma cell line was established in culture from a lymph node metastasis of malignant melanoma. Normal Balb/c mice were immunised with KAL cells. Splenocytes were used for fusion experiments using standard techniques. Hybridoma supernatants were tested for antibody binding activity using an indirect immunoperoxidase method on frozen sections from KAL tumour cells xenografted onto nude mice and human tonsils. KBA.62 was selected because of its reactivity with melanocytic proliferations on both frozen and paraffin wax sections. RESULTS--On immunoblotting, KBA.62 reacted with three bands of 140, 135 and 128 kD and two weak bands of 88 and 73 kD. In normal human tissues basal melanocytes in the epidermis did not react with this antibody and only occasional labelling of endothelial cells was noted. Of the human tumours, KBA.62 reacted strongly and uniformly with the majority of benign (21/21) and malignant (75/86) melanocytic proliferations. Staining was localised predominantly to the cell membrane with little or no cytoplasmic reactivity. Negative staining was observed in the majority of human non-melanocytic neoplasms, the exceptions being some carcinomas (11/89), particularly the well differentiated squamous cell type. This, however, was not thought to present a diagnostic problem. CONCLUSIONS--KBA.62 appears to be potentially useful in ascertaining the immunomorphological diagnosis of malignant melanoma in routinely processed paraffin wax sections.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7490315      PMCID: PMC502870          DOI: 10.1136/jcp.48.9.826

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  26 in total

1.  Specificity of antibody HMB-45.

Authors:  G A Herrera; C Hancock; B C Allen
Journal:  Arch Pathol Lab Med       Date:  1992-09       Impact factor: 5.534

2.  Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections.

Authors:  S R Shi; M E Key; K L Kalra
Journal:  J Histochem Cytochem       Date:  1991-06       Impact factor: 2.479

3.  Analysis of HMB-45 immunoreactivity in common and cellular blue nevi.

Authors:  W S Wood; V A Tron
Journal:  J Cutan Pathol       Date:  1991-08       Impact factor: 1.587

4.  S-100 protein expression by primary and metastatic adenocarcinomas.

Authors:  G A Herrera; E A Turbat-Herrera; R L Lott
Journal:  Am J Clin Pathol       Date:  1988-02       Impact factor: 2.493

5.  Production of anti-B monoclonal antibodies (DBB.42, DBA.44, DNA.7, and DND.53) reactive on paraffin-embedded tissues with a new B-lymphoma cell line grafted into athymic nude mice.

Authors:  T al Saati; S Caspar; P Brousset; S Chittal; P Caverivière; H Hounieu; N Dastugue; J B Idoipe; J Icart; C Mazerolles
Journal:  Blood       Date:  1989-11-15       Impact factor: 22.113

6.  Production of monoclonal antibodies using spleen cells from nude mice bearing human tumors.

Authors:  T Al Saati; A Blancher; P Calvas; I Neulat-Duga; G Delsol
Journal:  Ann Pathol       Date:  1987       Impact factor: 0.407

7.  Typical, dysplastic, congenital, and Spitz nevi: a comparative immunohistochemical study.

Authors:  J Palazzo; P H Duray
Journal:  Hum Pathol       Date:  1989-04       Impact factor: 3.466

8.  Unique proteins defined by monoclonal antibodies specific for human melanoma. Some potential clinical applications.

Authors:  R M Esclamado; A M Gown; A M Vogel
Journal:  Am J Surg       Date:  1986-10       Impact factor: 2.565

9.  Production of monoclonal antibodies to human estrogen-receptor protein (ER) using recombinant ER (RER).

Authors:  T al Saati; S Clamens; E Cohen-Knafo; J C Faye; H Prats; J M Coindre; J Wafflart; P Caverivière; F Bayard; G Delsol
Journal:  Int J Cancer       Date:  1993-10-21       Impact factor: 7.396

10.  Antibody BNH9 detects red blood cell-related antigens on anaplastic large cell (CD30+) lymphomas.

Authors:  G Delsol; A Blancher; T al Saati; E Ralfkiaer; A Lauritzen; L Bruigères; P Brousset; F Rigal-Huguet; C Mazerolles; A Robert
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

View more
  4 in total

1.  KBA62 and PNL2: 2 new melanoma markers-immunohistochemical analysis of 1563 tumors including metastatic, desmoplastic, and mucosal melanomas and their mimics.

Authors:  Phyu Phyu Aung; Maarit Sarlomo-Rikala; Jerzy Lasota; Jin-Ping Lai; Zeng-Feng Wang; Markku Miettinen
Journal:  Am J Surg Pathol       Date:  2012-02       Impact factor: 6.394

2.  Collagen XVII is expressed in malignant but not in benign melanocytic tumors and it can mediate antibody induced melanoma apoptosis.

Authors:  T Krenacs; G Kiszner; E Stelkovics; P Balla; I Teleki; I Nemeth; E Varga; I Korom; T Barbai; V Plotar; J Timar; E Raso
Journal:  Histochem Cell Biol       Date:  2012-06-12       Impact factor: 4.304

3.  Kba.62 and S100 protein expression in cytologic samples of metastatic malignant melanoma.

Authors:  Gulsun Erdag; Sinchita Roy Chowdhuri; Patricia Fetsch; Dana Erickson; Marybeth S Hughes; Armando C Filie
Journal:  Diagn Cytopathol       Date:  2013-04-03       Impact factor: 1.582

4.  A report of amelanotic malignant melanoma of the esophagus diagnosed appropriately with novel markers: A case report.

Authors:  Junya Kobayashi; Daisuke Fujimoto; Makoto Murakami; Yasuo Hirono; Takanori Goi
Journal:  Oncol Lett       Date:  2018-04-12       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.